HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >

Sort by: In order: Results/Page Authors/Record:
Export metadata:
Showing results 1 to 15 of 15
TypeAuthor(s)TitleOther TitlesCitationCitation(alt)Issue Date
article (author version)Jinushi, Masahisa; Chiba, Shigeki; Baghdadi, Muhammad; Kinoshita, Ichiro; Dosaka-Akita, Hirotoshi; Ito, Koyu; Yoshiyama, Hironori; Yagita, Hideo; Uede, Toshimitsu; Takaoka, AkinoriATM-Mediated DNA Damage Signals Mediate Immune Escape through Integrin-αvβ3-Dependent Mechanisms-Cancer Research-1-Jan-2012
article (author version)Takashima, Yuta; Kikuchi, Eiki; Kikuchi, Junko; Suzuki, Motofumi; Kikuchi, Hajime; Maeda, Makie; Shoji, Tetsuaki; Furuta, Megumi; Kinoshita, Ichiro; Dosaka-Akita, Hirotoshi; Sakakibara-Konishi, Jun; Konno, SatoshiBromodomain and extraterminal domain inhibition synergizes with WEE1-inhibitor AZD1775 effect by impairing nonhomologous end joining and enhancing DNA damage in nonsmall cell lung cancer-International journal of cancer-15-Feb-2020
article (author version)Takashima, Yuta; Sakakibara-Konishi, Jun; Hatanaka, Yutaka; Hatanaka, Kanako C.; Ohhara, Yoshihito; Oizumi, Satoshi; Hida, Yasuhiro; Kaga, Kichizo; Kinoshita, Ichiro; Dosaka-Akita, Hirotoshi; Matsuno, Yoshihiro; Nishimura, MasaharuClinicopathologic Features and Immune Microenvironment of Non-Small-cell Lung Cancer With Primary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors-Clinical lung cancer-Jul-2018
articleTakashina, Taichi; Kinoshita, Ichiro; Kikuchi, Junko; Shimizu, Yasushi; Sakakibara-Konishi, Jun; Oizumi, Satoshi; Nishimura, Masaharu; Dosaka-Akita, HirotoshiCombined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells-Cancer science-Jul-2016
articleSaito, Yoshitaka; Sakamoto, Tatsuhiko; Takekuma, Yoh; Kobayashi, Masaki; Okamoto, Keisuke; Shinagawa, Naofumi; Shimizu, Yasushi; Kinoshita, Ichiro; Sugawara, MitsuruDiabetes mellitus degenerates cisplatin-induced nephrotoxicity in short hydration method: a propensity score-matching analysis-Scientific reports-17-Dec-2022
articleTakeuchi, Satoshi; Shiga, Tohru; Hirata, Kenji; Taguchi, Jun; Magota, Keiichi; Ariga, Shin; Gouda, Tomohiro; Ohhara, Yoshihito; Homma, Rio; Shimizu, Yasushi; Kinoshita, Ichiro; Tsuji, Yasushi; Homma, Akihiro; Iijima, Hiroaki; Tamaki, Nagara; Dosaka-Akita, HirotoshiEarly prediction of lenvatinib treatment efficacy by using 18F-FDG PET/CT in patients with unresectable or advanced thyroid carcinoma that is refractory to radioiodine treatment : a protocol for a non-randomized single-arm multicenter observational study-BMJ Open-Nov-2018
article (author version)Shoji, Tetsuaki; Kikuchi, Eiki; Kikuchi, Junko; Takashima, Yuta; Furuta, Megumi; Takahashi, Hirofumi; Tsuji, Kosuke; Maeda, Makie; Kinoshita, Ichiro; Dosaka-Akita, Hirotoshi; Sakakibara-Konishi, Jun; Konno, SatoshiEvaluating the immunoproteasome as a potential therapeutic target in cisplatin-resistant small cell and non-small cell lung cancer-Cancer chemotherapy and pharmacology-May-2020
articleSakakibara-Konishi, Jun; Oizumi, Satoshi; Kikuchi, Junko; Kikuchi, Eiki; Mizugaki, Hidenori; Kinoshita, Ichiro; Dosaka-Akita, Hirotoshi; Nishimura, MasaharuExpression of Bim, Noxa, and Puma in non-small cell lung cancer-BMC Cancer-12-Jul-2012
article (author version)Mizumachi, Takatsugu; Homma, Akihiro; Kakizaki, Tomohiko; Sakashita, Tomohiro; Kano, Satoshi; Hatakeyama, Hiromitsu; Tsuchiya, Kazuhiko; Yasuda, Koichi; Onimaru, Rikiya; Shirato, Hiroki; Taguchi, Jun; Shimizu, Yasushi; Kinoshita, Ichiro; Akita, Hirotoshi; Fukuda, SatoshiFeasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with concurrent weekly cisplatin chemoradiotherapy for locally advanced head and neck squamous cell carcinoma-International journal of clinical oncology-Jun-2015
articleTakeuchi, Satoshi; Goda, Tomohiro; Taguchi, Jun; Douhata, Yuichi; Honma, Rio; Ariga, Shin; Ohhara, Yoshihito; Shimizu, Yasushi; Kinoshita, Ichiro; Fukuda, Izumi; Nagashima, Yoji; Akita, HirotoshiLate Onset of Non-islet Cell Tumor Hypoglycemia Managed via Multidisciplinary Treatment in a Patient with a Solitary Fibrous Tumor-Internal medicine-15-Aug-2018
article (author version)Sakakibara-Konishi, Jun; Oizumi, Satoshi; Kinoshita, Ichiro; Shinagawa, Naofumi; Kikuchi, Junko; Kato, Mototsugu; Inoue, Tetsuya; Katoh, Norio; Onimaru, Rikiya; Shirato, Hiroki; Dosaka-Akita, Hirotoshi; Nishimura, MasaharuPhase I study of concurrent real-time tumor-tracking thoracic radiation therapy with paclitaxel and carboplatin in locally advanced non-small cell lung cancer-Lung Cancer-Nov-2011
article (author version)Takashina, Taichi; Asahina, Hajime; Oizumi, Satoshi; Yamada, Noriyuki; Harada, Masao; Takamura, Kei; Yokouchi, Hiroshi; Harada, Toshiyuki; Honjo, Osamu; Ogi, Takahiro; Morikawa, Naoto; Kinoshita, Ichiro; Honda, Ryoichi; Nakano, Kosuke; Kanazawa, Kenya; Amano, Toraji; Dosaka-Akita, Hirotoshi; Isobe, Hiroshi; Nishimura, MasaharuA phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101)-International journal of clinical oncology-Dec-2018
article (author version)Asahina, Hajime; Oizumi, Satoshi; Inoue, Akira; Kinoshita, Ichiro; Ishida, Takashi; Fujita, Yuka; Sukoh, Noriaki; Harada, Masao; Maemondo, Makoto; Saijo, Yasuo; Dosaka-Akita, Hirotoshi; Isobe, Hiroshi; Nukiwa, Toshihiro; Nishimura, MasaharuPhase II Study of Gefitinib Readministration in Patients with Advanced Non-Small Cell Lung Cancer and Previous Response to Gefitinib-Oncology : International Journal for Cancer Research and Treatment-Apr-2011
article (author version)Ikezawa, Yasuyuki; Asahina, Hajime; Oizumi, Satoshi; Watanabe, Masahiro; Takamura, Kei; Kawai, Yasutaka; Yamada, Noriyuki; Harada, Toshiyuki; Kinoshita, Ichiro; Fujita, Yuka; Miyauchi, Eisaku; Ogi, Takahiro; Amano, Toraji; Furuta, Megumi; Sakakibara-Konishi, Jun; Nishihara, Hiroshi; Dosaka-Akita, Hirotoshi; Isobe, Hiroshi; Nishimura, MasaharuA randomized phase II trial of erlotinib vs. S-1 as a third- or fourth-line therapy for patients with wild-type EGFR non-small cell lung cancer (HOT1002)A randomized phase II trial of erlotinib versus S-1 as a third- or fourth-line therapy for patients with wild-type EGFR non-small cell lung cancer (HOT1002)Cancer chemotherapy and pharmacology-Nov-2017
article (author version)Chiba, Shigeki; Baghdadi, Muhammad; Akiba, Hisaya; Yoshiyama, Hironori; Kinoshita, Ichiro; Dosaka-Akita, Hirotoshi; Fujioka, Yoichiro; Ohba, Yusuke; Gorman, Jacob V.; Colgan, John D.; Hirashima, Mitsuomi; Uede, Toshimitsu; Takaoka, Akinori; Yagita, Hideo; Jinushi, MasahisaTumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1-Nature Immunology-Sep-2012
Showing results 1 to 15 of 15

 

Hokkaido University